INS and preeclampsia: There was a reduction in the primary outcomes of NICU admission (metformin 43.8% vs. metformin + insulin 23.3% vs. insulin 69.9%, p < 0.01) and neonatal hypoglycaemia (metformin 25.0% vs. metformin + insulin 7.8% vs. insulin 30.0%, p < 0.01) in the metformin (and metformin/insulin) treated group, as well as a reduction in a number of secondary outcomes including gestational hypertension and weight gain, and an increase in SGA infants.18